{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:44:56Z","timestamp":1785422696462,"version":"3.56.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013699","name":"Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U24CA247648"],"award-info":[{"award-number":["U24CA247648"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016058"],"award-info":[{"award-number":["P30 CA016058"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"OSUCCC Pelotonia Foundation"},{"name":"Pelotonia Fellowship Program"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Decitabine is a DNA hypomethylating agent used in the treatment of patients with myelodysplastic syndromes and acute myeloid leukemia that is administered intravenously because of its poor oral bioavailability. An oral medication containing decitabine and cedazuridine has been approved for human use and has been shown to provide equivalent systemic exposure to decitabine compared with the drug given intravenously. Although the ability of ceduazuridine to boost the oral bioavailability of decitabine has been ascribed to its ability to inhibit first-pass metabolism mediated by cytidine deaminase (CDA), the precise mechanisms underlying this decitabine\u2013cedazuridine interaction remain incompletely understood. We evaluated the pharmacokinetic profile of decitabine in wild-type (WT), CDA-knockout (KO), and concentrative nucleoside transporter 1 (CNT1)\u2013KO mice after oral or intravenous decitabine (10 mg\/kg) with or without cedazuridine. The oral bioavailability of decitabine in WT mice was \u223c15%, and the area under the curve (AUC) of oral decitabine increased \u223csevenfold in CDA-KO mice and by \u223cfivefold in WT mice co-treated with cedazuridine. Cedazuridine also increased the urinary excretion of radiolabeled decitabine from \u223c20% to \u223c40% of the dose in WT to \u223c60% in CDA KO, indicating a CDA-independent mechanism. CNT1-KO mice given decitabine with cedazuridine showed \u223c60% lower AUC and \u223c1.8-fold higher urinary loss than WT mice. Our results demonstrate that cedazuridine prevents extensive first-pass metabolism of decitabine primarily through CDA inhibition but also enhances renal elimination by affecting CNT1-mediated tubular reabsorption, thereby highlighting renal transport as a source of pharmacokinetic drug\u2013drug interactions with decitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study reveals that cedazuridine affects oral decitabine not only by inhibiting CDA metabolism but also by altering CNT1-mediated renal reabsorption. Defining these mechanisms advances understanding of decitabine\u2019s pharmacokinetics, explains interpatient variability, and informs safer, more effective use of oral hypomethylating therapy in myeloid malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0764","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:49:05Z","timestamp":1772470145000},"page":"648-656","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-8460","authenticated-orcid":false,"given":"Nadeen","family":"Anabtawi","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1361-8654","authenticated-orcid":false,"given":"Thomas","family":"Drabison","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-5098","authenticated-orcid":false,"given":"Alexander F.","family":"Ham","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-7408","authenticated-orcid":false,"given":"Mike","family":"Boeckman","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-4617","authenticated-orcid":false,"given":"Jack C.","family":"Stromatt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1409","authenticated-orcid":false,"given":"Shelley J.","family":"Orwick","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4413-5711","authenticated-orcid":false,"given":"Daelynn R.","family":"Buelow","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5200-7461","authenticated-orcid":false,"given":"Tejinder","family":"Kaur","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-2630","authenticated-orcid":false,"given":"Eman A.","family":"Ahmed","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-675X","authenticated-orcid":false,"given":"Eric D.","family":"Eisenmann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2958-5773","authenticated-orcid":false,"given":"Rajgopal","family":"Govindarajan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-6644","authenticated-orcid":false,"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-3252","authenticated-orcid":false,"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University Division of Pharmaceutics and Pharmacology, College of Pharmacy, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026032401030053600_bib1","first-page":"53","article-title":"Decitabine in the treatment of acute myeloid leukemia in elderly patients","volume":"6","author":"Malik","year":"2014","journal-title":"Cancer Manag Res"},{"key":"2026032401030053600_bib2","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026032401030053600_bib3","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12325-021-01948-8","article-title":"The clinical value of decitabine monotherapy in patients with acute myeloid leukemia","volume":"39","author":"Santini","year":"2022","journal-title":"Adv Ther"},{"key":"2026032401030053600_bib4","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"2026032401030053600_bib5","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1158\/1078-0432.CCR-08-2783","article-title":"Targeting DNA methylation","volume":"15","author":"Issa","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026032401030053600_bib6","doi-asserted-by":"crossref","first-page":"11797","DOI":"10.1073\/pnas.91.25.11797","article-title":"Toxicity of 5-aza-2\u2032-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation","volume":"91","author":"J\u00fcttermann","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026032401030053600_bib7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","article-title":"Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity","volume":"14","author":"Camiener","year":"1965","journal-title":"Biochem Pharmacol"},{"key":"2026032401030053600_bib8","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"key":"2026032401030053600_bib9","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine\u2013cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol"},{"key":"2026032401030053600_bib10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","article-title":"Decitabine\/cedazuridine: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"2026032401030053600_bib11","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/bjh.19769","article-title":"Oral decitabine\u2013cedazuridine in acute myeloid leukaemia","volume":"205","author":"Bouligny","year":"2024","journal-title":"Br J Haematol"},{"key":"2026032401030053600_bib12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"2026032401030053600_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/17474086.2025.2487605","article-title":"Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients","volume":"18","author":"Niscola","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"2026032401030053600_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/15257771003729823","article-title":"Role of nucleoside transporters in nucleoside-derived drug sensitivity","volume":"29","author":"Molina-Arcas","year":"2010","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2026032401030053600_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","article-title":"The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs","volume":"26","author":"Zhang","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"2026032401030053600_bib16","doi-asserted-by":"crossref","first-page":"e00534","DOI":"10.1002\/prp2.534","article-title":"Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice","volume":"7","author":"Anderson","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"2026032401030053600_bib17","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1021\/mp200647a","article-title":"Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(\u2212\/\u2212) mice","volume":"9","author":"Moss","year":"2012","journal-title":"Mol Pharm"},{"key":"2026032401030053600_bib18","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41467-023-38789-8","article-title":"Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice","volume":"14","author":"Persaud","year":"2023","journal-title":"Nat Commun"},{"key":"2026032401030053600_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2022.2112175","article-title":"Important roles of transporters in the pharmacokinetics of anti-viral nucleoside\/nucleotide analogs","volume":"18","author":"Yang","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026032401030053600_bib20","doi-asserted-by":"crossref","first-page":"124209","DOI":"10.1016\/j.jchromb.2024.124209","article-title":"Pharmacokinetic assessment of low dose decitabine in combination therapies: development and validation of a sensitive UHPLC-MS\/MS method for murine plasma analysis","volume":"1242","author":"Anabtawi","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2026032401030053600_bib21","doi-asserted-by":"crossref","first-page":"e3056","DOI":"10.21769\/BioProtoc.3056","article-title":"Murine pharmacokinetic studies","volume":"8","author":"Leblanc","year":"2018","journal-title":"Bio Protoc"},{"key":"2026032401030053600_bib22","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood.V118.21.3801.3801","article-title":"A phase 1 study to assess the absolute bioavailability and safety of an oral solution of decitabine in subjects with myelodysplastic syndromes (MDS)","volume":"118","author":"Mistry","year":"2011","journal-title":"Blood"},{"key":"2026032401030053600_bib23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/10781552241238979","article-title":"Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes\/neoplasms and acute myeloid leukemia: a multidisciplinary review","volume":"30","author":"Haumschild","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2026032401030053600_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11523-020-00709-x","article-title":"Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model","volume":"15","author":"Ramsey","year":"2020","journal-title":"Target Oncol"},{"key":"2026032401030053600_bib25","volume-title":"Inaqovi: EPAR \u2013 public assessment report [Internet]","author":"European Medicines Agency","year":"2021"},{"key":"2026032401030053600_bib26","volume-title":"Multidiscipline review: NDA 212576, Inqovi (decitabine\/cedazuridine) [Internet]. Silver Spring (MD)","author":"U.S. Food and Drug Administration","year":"2020"},{"key":"2026032401030053600_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bdd.2128","article-title":"Effects of renal impairment on transporter-mediated renal reabsorption of drugs and renal drug\u2013drug interactions: a simulation-based study","volume":"39","author":"Follman","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"2026032401030053600_bib28","doi-asserted-by":"crossref","first-page":"101406","DOI":"10.1016\/j.jgo.2022.11.005","article-title":"Hypomethylating agent-based therapies in older adults with acute myeloid leukemia \u2013 a joint review by the Young International Society of Geriatric Oncology and European Society for Blood and Marrow Transplantation Trainee Committee","volume":"14","author":"Neuendorff","year":"2023","journal-title":"J Geriatr Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0764\/3744588\/crc-25-0764.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/648\/3750246\/crc-25-0764.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/648\/3750246\/crc-25-0764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:03:15Z","timestamp":1774328595000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/648\/775586\/Mechanisms-Underlying-Cedazuridine-Mediated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0764","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31840708","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840729","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840717","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840741","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840723","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840711","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840732","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840720","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840705","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840726","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840714","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840735","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31840702","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8378665","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}